Surgical treatment strategies for invasive thymoma
Review Article on Thymoma

Surgical treatment strategies for invasive thymoma

Soichiro Funaki1, Yasushi Shintani1, Eriko Fukui1, Ryu Kanzaki1, Takashi Kanou1, Naoko Ose1, Masato Minami1, Meinoshin Okumura2

1Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan; 2General Thoracic Surgery, Osaka Toneyama Medical Center, Osaka, Japan

Contributions: (I) Conception and design: S Funaki, M Okumura; (II) Administrative support: Y Shintani; (III) Provision of study materials or patient records: Y Shintani; (IV) Collection and assembly of data: Y Shintani; (V) Data analysis and interpretation: T Kanou; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Soichiro Funaki, MD, PhD. Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, L-5 2-2 Yamadaoka, Suita-city, Osaka 565-0897, Japan. Email:

Abstract: A thymoma is a common anterior thymus mediastinal tumor composed of atypical epithelial tumor cells, though the morbidity rate is lower as compared to other types of thoracic malignancy such as lung cancer and lung metastasis from another primary cancer. As a result, clinical data regarding thymomas have not been well discussed as compared to those of other carcinomas. Also, because of the low morbidity rate and insufficient clinical experience, oncological characteristics and clinical treatment options are poorly understood. Surgical complete resection is the most reliable option for clinical treatment of a thymoma. This tumor can easily develop adjacent to several different structures and nearby organs, such as the pericardium, lungs, and great vessels, which are easily invaded when the size is large, and a combined resection is then needed. When en bloc resection is considered to be difficult based on evaluation with preoperative modalities, induction chemotherapy followed by surgery is recommended. Moreover, when pleural dissemination is revealed during pre- or peri-operative procedures, volume reduction surgery has been reported by several groups to extend prognosis. On the other hand, in cases with a small-sized tumor, a minimally invasive surgical procedure, such as video-assisted thoracic surgery (VATS) or robotic-assisted thoracic surgery (RATS), is usually selected. Because of the wide variety of cases with thymoma, a deliberate strategy and skillful techniques are necessary for effectual surgical treatment. In this review, we discuss strategies that have been shown to be effective for treating patients with early and advanced thymoma, including those with involved adjacent organs.

Keywords: Surgical approach; advanced thymoma; en bloc resection

Submitted Nov 19, 2019. Accepted for publication Jun 15, 2020.

doi: 10.21037/jtd-19-3045


It is well accepted that the main effective treatment for a thymic epithelial tumor (TET), including thymoma and thymic cancer, is complete resection surgery. Among TETs, a thymoma is most frequent, though still relatively rare as compared to all types of thoracic malignancy including lung cancer, thus no standard therapy has been established. A TET usually develops in the anterior mediastinum in close proximity to several important structures and organs, such as pericardium, great vessels, lungs, and heart, as well as others. When small in size and early Masaoka stage, no invasion of surrounding adjacent organs occurs and tumor resection in such early-stage cases is relatively easily completed. Preoperatively, an appropriate surgical method must be considered, such as a conventional median sternotomy (MS) or minimal invasive approach. In cases with advanced Masaoka stage, or a large sized tumor and aggressive histological types, such as type B2/B3 or thymic cancer, invasion of adjacent organs can easily occur. For those cases, an en bloc resection is generally considered to be difficult and only incomplete resection is sometimes achieved. Surgery alone in affected patients often does not control the disease or improve curability, thus a therapeutic strategy with surgical treatment as well as multimodality therapy (MT) should be planned. Several studies have reported that induction therapy (IT) followed by surgery resulted in improved outcomes (1,2).

For this study, we focused on potential pitfalls when treating these cases and review recently published reports concerning surgical treatment for advanced stage TETs. Our findings show that the most effective surgical strategy will differ depending on what organs have been invaded by the tumor, and we present possible surgical strategies and approaches to be considered, especially for advanced TET cases. Recently, minimally invasive surgery (MIS) procedures including robotic-assisted thoracic surgery (RATS) have become prominent (3). Here, we also introduce an MIS approach for patients with advanced stage TET.

Fundamental surgical treatment principles

Surgical treatment for advanced thymoma cases is generally radical resection of the tumor and involved organs. Imaging to determine whether the tumor has invaded adjacent structures is very important, with enhanced high-resolution computed tomography, magnetic resonance imaging (MRI), and positron emission tomography (PET) examinations performed preoperatively (4). When a combined resection including invaded organs is necessary, a MS is the generally chosen surgical approach. To determine dissemination into the thoracic cavity and evaluate involved organs, thoracoscopy is a useful tool. When tumor invasion includes a wide area of a lung, resection of that organ is required, for which a one-lung ventilation technique should be chosen to provide a wide surgical field for easy surgical manipulation. Mainstem methods used to achieve lung separation include utilization of a double-lumen endotracheal tube or placement of a bronchial blocker through a single-lumen endotracheal tube.

MIS for advanced thymoma

Video-assisted thoracic surgery (VATS) is a minimally invasive technique usually applied to cases with early stage malignancy including TET. However, VATS for an anterior thoracic tumor has disadvantages for advanced cases as compared to a conventional MS, because surgical manipulation for resection and reconstruction is difficult with the mediastinum space is limited. Obtaining a wide surgical space in narrow mediastinum tissue is a significant issue with a VATS approach, though several groups have reported surgical procedures to solve associated problems. Kido et al. demonstrated an intrasternal technique termed the subxiphoid approach (5). Sakamaki et al. showed the utility of a sternal lifting technique by use of the Laparolift system and reported favorable intermediate-term oncologic outcomes after a VATS thymectomy (VATS-T) for early-stage thymoma in patients who underwent an open thymectomy (6,7). Additionally, Takeo et al. and Ohta et al. presented a sternum lifting method that utilizes retractors and costal hooks (8-10). Most of those explained sternum lifting techniques, which subsequently have been widely used for extended thymectomy and thymothymectomy procedures via VATS for myasthenia gravis (MG) and early stage thymoma patients who had no invasion to other organs.

More recently, several groups have reported surgical techniques for treating cases of advanced thymoma with VATS. Hirai et al. introduced a method that combines video-assisted thoracoscopic thymectomy (VAT-T) with lateral thoracotomy for stage II and some stage III thymomas with local lung and/or pericardium invasion, and Yano et al. reported a case in which a thoracoscopic thymectomy with partial resection of the brachiocephalic vein (BCV) was performed by use of a subxiphoid approach (11,12). Quite recently, a retractor with a gas insufflation tube and multiple access ports was developed, and shown able to create a wide surgical view and space, thus providing easier surgical manipulation. In addition, Okuda et al. reported a case of thymothymectomy with pulmonary partial resection using VATS for a subxiphoid approach with use of a CO2 insufflation multiport system (13). However, the feasibility of VATS for an advanced thymoma and resulting clinical outcomes remain unclear. Kimura et al. noted that careful attention is required for MIS in cases with a large or cystic thymoma, because of potential risk for intraoperative capsule injury and subsequent pleural dissemination (14).


Along with progress in imaging quality and medical technology, new systems such as RATS have been developed, with the da Vinci Surgical System® a pioneer in this field. That system has been shown to provide surgeons with superior visualization, enhanced dexterity, and greater precision, as well as intraoperative patient comfort. Moreover, with it the surgeon is able to perform procedures with lower levels of invasion for complex dissection or reconstruction as compared to traditional VATS. Several reports have also demonstrated cases of early as well as advanced thymoma treatment completed by use of RATS (15-17). On the other hand, the feasibility of RATS for TET along with resulting clinical outcomes remain unclear.

Advanced staging, Masaoka stage III-IV

Principles of treatment for advanced TET

An advanced thymoma is typically Masaoka stage III or IV, with a large size and possible invasion of nearby organs and structures. When an advanced stage TET is suspected in pretreatment imaging findings, such as those obtained by CT, MRI, or PET, the treatment plan should be carefully discussed and decided together with an experienced surgeon. Prior to finalizing the treatment plan, a histopathological examination is needed, for which a CT-guided biopsy is useful and can provide sufficient specimens. Furthermore, the risk of tumor dissemination into the thoracic cavity with a CT-guided biopsy is lower as compared to a biopsy using a VATS approach. When histopathological analysis results reveal thymoma or thymic carcinoma, with great vessel invasion or dissemination to thoracic cavity suspected, and complete resection considered to be difficult, IT followed by surgery should be the strategy used (1,2).

Multimodality treatment

Treatment of a locally invasive thymoma is considered to be difficult, because the high rate of incomplete resection results in a high rate of recurrence. To achieve complete resection of such an advanced thymoma, IT is sometimes performed, including chemotherapy or chemoradiation therapy. A multimodality therapeutic approach such as IT followed by complete resection is considered to improve the outcome of patients with an advanced thymoma (18). In fact, several reports discussing MT for advanced thymoma and thymic carcinoma have been presented, including induction chemotherapy regimens. Yokoi et al. reported cisplatin, doxorubicin, and methylprednisolone (CAMP) IT to be effective chemotherapy for advanced thymoma (2), and Korst et al. noted that induction chemoradiotherapy is a viable option for patients with a locally advanced thymic tumor and that its use resulted in a high rate of complete surgical resection (19). Use of adjuvant therapy has also been discussed, with Leuzzi et al. showing its benefits for locally advanced thymoma (20). On the other hand, postoperative radiation therapy (PORT) is controversial. Omasa found that PORT did not increase recurrence-free or overall survival for stage II or III thymoma cases, though recurrence-free survival was increased in stage II and III thymic carcinoma cases (21), with the same results demonstrated by Utsumi et al. (22).

Selection of surgical approach

A MS is the standard surgical approach for locally advanced TET. That procedure provides a wide surgical view with multiple diversity when used with a usual thymothymectomy or extended thymectomy, including combined resection and reconstruction with an involved adjacent organ located near the center of the mediastinum, such as left BCV, pericardium, and deep lymphoid node dissection. Moreover, for partial resection of an involved lung near the anterior hilum, MS also provides a sufficient surgical view. However, when the tumor involves the hilum including a wide area of the lung or pulmonary artery, resection of lung parenchyma greater than a single lobe is needed and the surgical view provided by only MS may sometimes be insufficient. To obtain a wider view during surgery and increase the safety of surgical manipulation, a hemi-clamshell (HCS) incision is useful. Recently, our group reported that an HCS approach was helpful for lung resection and dissemination around the thoracic cavity performed for advanced thymic malignancy with hilar invasion by providing multiple access paths to the tumor and hilum, allowing for a sufficient surgical margin (23).

Combined resection with adjacent involved organs

Phrenic nerve (PN) resection

A locally advanced thymoma (greater than Masaoka stage III) often involves the PN due to a mediastina tumor location. For only tumor curability, an en bloc resection with the PN is better than preserving that nerve. However, a combined resection including the PN is controversial in patients with severe MG or extensive comorbidities. Whether a combined resection including the PN should be performed has been discussed. Yano et al. reported that PN resection decreased pulmonary function, though there was no significant difference between cases with and without resection (24). Also, Hamdi et al. noted that sparing the PN during thymoma resection achieved good long-term and disease-free survival in high-risk patients as compared with an en bloc PN resection, though concluded that it introduced a higher risk of recurrence despite performance of adjuvant radiation therapy (ART) (25). Moreover, Aprile et al. recently documented that PN preservation in cases of invasive thymoma is feasible and may result in acceptable local control of disease (26). On the other hand, when a combined resection including the PN is truly necessary or the nerve has received accidental injury resulting in paralysis during the operation, diaphragm plication is recommended. Tokunaga et al. reported that diaphragm plication following PN resection can prevent pulmonary dysfunction (27).

Superior vena cava resection and reconstruction

Radical resection of the tumor along with involved neighboring structures is key to prolonging overall survival of patients with an invasive thymoma. Additionally, combined resection and reconstruction of involved mediastinal great vessels is also considered to be feasible though challenging, as shown in retrospective findings (28,29). Most of those studies noted that a combined resection of the superior vena cava (SVC) and BCV is widely performed for cases of invasion by thymoma or thymic carcinoma. When the tumor has invaded a part of the vessel, resection of the invaded wall and direct suturing of the defect may be feasible. However, when a wide area of the vessel shows invasion, vessel replacement is required. There is variety of choices for vessel replacement that includes anastomosis of the SVC and BCV, including SVC-SVC, left BCV-right atrial appendage (RAA), and right/left BCV-RAA. As for the procedure used for reconstruction of those vessels, when a double BCV resection and reconstruction are performed, it is recommended that the graft first be anastomosed between the right appendage and left BCV in order to reduce clamping time. For SVC replacement, a polytetrafluoroethylene (PTFE) Gore-Tex synthetic prosthesis is usually employed, and a recent report noted use of an autologous pericardium conduit in cases of SVC replacement in which graft patency showed a good outcome (28,29).

Aortic arch combined resection and reconstruction

The combination of resection of an invaded artery and graft replacement in association with TET is rarely performed. As for cases of thymoma, a few reports have noted combined resection of the aortic arch, though we do not usually perform combined resection of the artery and reconstruction at our institution (30).

The feasibility as well as clinical outcomes of combined arterial resection in patients with an advanced thymoma remain unclear. We usually perform debulking surgery for volume reduction in thymoma cases (31). In those with a thymic carcinoma that has invaded an artery, especially the aortic arch, we aim to perform an en bloc resection of the tumor and invaded aortic arch, along with reconstruction for complete resection (32). In such complicated cases, careful preoperative evaluations should be made in discussions with an experienced board-certificated thoracic surgeon team with extensive experience as well as the cardiovascular surgeon team, with careful planning the goal. Recently, Shintani et al. presented a new surgical approach for en bloc resection of a tumor invading the aortic arch and replacement using total rerouting of supra-arch vessels, which may be useful for en bloc resection in cases with an advanced TET showing invasion of the aortic arch (33).

Surgical resection of recurrent thymoma

When possible, surgical resection is the primary treatment for a thymoma, as it provides the best assurance of good long-term prognosis. However, recurrence following such an operation can occur in 10–30% of treated patients, even years after the initial surgery. The most common is dissemination into the thoracic cavity. Several retrospective studies have found that surgical treatment for a recurrent thymoma may improve clinical outcome (34-39). Of various sites of metastasis reported, including local, distant, and dissemination, the optimal treatment method for a thymoma with pleural dissemination remains challenging. A number of different groups have reported results of surgical treatment for pleural recurrent thymoma. Lucchi et al. and Kimura et al. noted that surgical resection of a thymoma with pleural dissemination is feasible and safe (36-38). As for surgical procedures employed for pleural dissemination, extrapleural pneumonectomy (EPP), total pleurectomy (TP), and local pleurectomy (LP) have been demonstrated in previous reports (40-44). For an advanced thymoma with multiple dissemination sites throughout the thoracic cavity, as well as cases with severe invasion of the main pulmonary artery or a wide area of lung parenchyma, an EPP can sometimes be adapted, as noted in several retrospective studies of EPP for advanced thymoma. Some Japanese groups have also reported that use of an EPP as part of MT for selected patients showed potential for improving local control, leading to a cure (40-44). The indications for an EPP should be considered for selected patients whose cardiopulmonary function has been preoperatively evaluated and found to be sufficient for undergoing a pneumonectomy. In addition, an EPP should be performed by a surgical team with ample experience. As part of MT for a thymoma with pleural dissemination, EPP offers good local control and may lead to a cure.

Adjuvant therapy

Disease control for an advanced thymoma by surgery alone is sometimes difficult, thus strategies that include other modalities such as induction and radiation therapy are necessary. However, the effects of adjuvant therapy remain unclear because of the paucity of reports presented thus far. Furthermore, the effects of adjuvant chemotherapy (ACT) and radiation therapy (ART) are controversial, as Utsumi et al. reported that ART did not improve outcome and a review by Hamaji et al. showed that outcomes were also not improved by ACT (22,45,46).

Concluding remarks

TET occurrence is relatively rare and no standard therapy has been established. For early stage cases, VATS and RATS have become standard approaches. As for advanced stage thymoma, a radical resection is considered to be the primary therapy, though, since surgery alone does not necessarily control disease, a multimodality treatment strategy is often needed. Careful preoperative evaluations and surgical indication decisions should be made in consultations with an established cancer board comprised of doctors from various related departments, while surgical procedures should be performed by an experienced surgeon.


Funding: None.


Provenance and Peer Review: This article was commissioned by the Guest Editors (Dragana Jovanovic and Semra Bilaceroglu) for the series “Thymoma” published in Journal of Thoracic Disease. The article was sent for external peer review organized by the Guest Editors and the editorial office.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at: The series “Thymoma” was commissioned by the editorial office without any funding or sponsorship. YS serves as an unpaid editorial board member of Journal of Thoracic Disease from Sept 2019 to Aug 2021. The other authors have no other conflicts of interest to declare.

Ethical Statement: All authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See:


  1. Huang J, Rizk NP, Travis WD, et al. Feasibility of multimodality therapy including extended resections in stage IVA thymoma. J Thorac Cardiovasc Surg 2007;134:1477-83. [Crossref] [PubMed]
  2. Yokoi K, Matsuguma H, Nakahara R, et al. Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone. J Thorac Oncol 2007;2:73-8. [Crossref] [PubMed]
  3. Okumura M, Shintani Y, Ohta M, et al. Minimally invasive surgical procedures for thymic disease in Asia. J Vis Surg 2017;27;3:96.
  4. Korst RJ, Fernando S, Catlin AC, et al. Contributors to the International Thymic Malignancy Interest Group (ITMIG) Prospective Database. Positron Emission Tomography in Thymic Tumors: Analysis Using a Prospective Research Database. Ann Thorac Surg 2017;104:1815-20. [Crossref] [PubMed]
  5. Kido T, Hazama K, Inoue Y, et al. Resection of Anterior Mediastinal Masses Through an Infrasternal Approach. Ann Thorac Surg 1999;67:263-5. [Crossref] [PubMed]
  6. Sakamaki Y, Oda T, Kanazawa G, et al. Intermediate-term oncologic outcomes after video-assisted thoracoscopic thymectomy for early-stage thymoma. J Thorac Cardiovasc Surg 2014;148:1230-7.e1. [Crossref] [PubMed]
  7. Sakamaki Y, Kido T, Yasukawa M. Alternative choices of total and partial thymectomy in video-assisted resection of noninvasive thymomas. Surg Endosc 2008;22:1272-7. [Crossref] [PubMed]
  8. Takeo S, Sakada T, Yano T. Video-assisted extended thymectomy in patients with thymoma by lifting the sternum. Ann Thorac Surg 2001;71:1721-3. [Crossref] [PubMed]
  9. Takeo S, Tsukamoto S, Kawano D, et al. Outcome of an original video-assisted thoracoscopic extended thymectomy for thymoma. Ann Thorac Surg 2011;92:2000-5. [Crossref] [PubMed]
  10. Ohta M, Hirabayasi H, Okumura M, et al. Thoracoscopic thymectomy using anterior chest wall lifting method. Ann Thorac Surg 2003;76:1310-1. [Crossref] [PubMed]
  11. Hirai K, Ibi T, Bessho R, et al. Video-assisted thoracoscopic thymectomy (VAT-T) with lateral thoracotomy for stage II and III thymoma. Ann Thorac Cardiovasc Surg 2013;19:79-82. [Crossref] [PubMed]
  12. Yano M, Okuda K, Kawano O, et al. Thoracoscopic Thymectomy with Tangential Partial Resection of the Innominate Vein. Ann Thorac Cardiovasc Surg 2017;23:207-10. [Crossref] [PubMed]
  13. Okuda K, Haneda H, Yokota K, et al. Thymothymectomy with pulmonary partial resection using the subxiphoid approach: how to do it? Surg Today 2018;48:1096-9. [Crossref] [PubMed]
  14. Kimura T, Inoue M, Kadota Y, et al. The oncological feasibility and limitations of video-assisted thoracoscopic thymectomy for early-stage thymomas. Eur J Cardiothorac Surg 2013;44:e214-8. [Crossref] [PubMed]
  15. Yang HC, Coyan G, Vercauteren M, et al. Robot-assisted en bloc anterior mediastinal mass excision with pericardium and adjacent lung for locally advanced thymic carcinoma. J Vis Surg 2018;4:115. [Crossref] [PubMed]
  16. Mussi A, Fanucchi O, Davini F, et al. Robotic extended thymectomy for early-stage thymomas. Eur J Cardiothorac Surg 2012;41:e43-6. [Crossref] [PubMed]
  17. Marulli G, Maessen J, Melfi F, et al. Multi-institutional European experience of robotic thymectomy for thymoma. Ann Cardiothorac Surg 2016;5:18-25. [PubMed]
  18. Kanzaki R, Kanou T, Ose N, et al. Long-term outcomes of advanced thymoma in patients undergoing preoperative chemotherapy or chemoradiotherapy followed by surgery: a 20-year experience. Interact Cardiovasc Thorac Surg 2019;28:360-7. [Crossref] [PubMed]
  19. Korst RJ, Bezjak A, Blackmon S, et al. Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: a phase II, multi-institutional clinical trial. J Thorac Cardiovasc Surg 2014;147:36-44, 46. [Crossref] [PubMed]
  20. Leuzzi G, Rocco G, Ruffini E, et al. Multimodality therapy for locally advanced thymomas: A propensity score-matched cohort study from the European Society of Thoracic Surgeons Database. J Thorac Cardiovasc Surg 2016;151:47-57.e1. [Crossref] [PubMed]
  21. Omasa M, Date H, Sozu T, et al. Japanese Association for Research on the Thymus. Postoperative radiotherapy is effective for thymic carcinoma but not for thymoma in stage II and III thymic epithelial tumors: the Japanese Association for Research on the Thymus Database Study. Cancer 2015;121:1008-16. [Crossref] [PubMed]
  22. Utsumi T, Shiono H, Kadota Y, et al. Postoperative radiation therapy after complete resection of thymoma has little impact on survival. Cancer 2009;115:5413-20. [Crossref] [PubMed]
  23. Fujiwara A, Funaki S, Ose N, et al. Surgical resection for advanced thymic malignancy with pulmonary hilar invasion using hemi-clamshell approach. J Thorac Dis 2018;10:6475-81. [Crossref] [PubMed]
  24. Yano M, Sasaki H, Moriyama S, et al. Preservation of phrenic nerve involved by stage III thymoma. Ann Thorac Surg 2010;89:1612-9. [Crossref] [PubMed]
  25. Hamdi S, Mercier O, Fadel E, et al. Is scarifying the phrenic nerve during thymoma resection worthwhile? Eur J Cardiothorac Surg 2014;45:e151-5. [Crossref] [PubMed]
  26. Aprile V, Bertoglio P, Korasidis S, et al. Nerve-Sparing Surgery in Advanced Stage Thymomas. Ann Thorac Surg 2019;107:878-84. [Crossref] [PubMed]
  27. Tokunaga T, Sawabata N, Kadota Y, et al. Efficacy of intra-operative unilateral diaphragm plication for patients undergoing unilateral phrenicotomy during extended surgery. Eur J Cardiothorac Surg 2010;38:600-3. [Crossref] [PubMed]
  28. Sun Y, Gu C, Shi J, Fang W, et al. Reconstruction of mediastinal vessels for invasive thymoma: a retrospective analysis of 25 cases. J Thorac Dis 2017;9:725-33. [Crossref] [PubMed]
  29. Shintani Y, Ohta M, Minami M, et al. Long-term graft patency after replacement of the brachiocephalic veins combined with resection of mediastinal tumors. J Thorac Cardiovasc Surg 2005;129:809-12. [Crossref] [PubMed]
  30. Fujino S, Tezuka N, Watarida S, et al. Reconstruction of the aortic arch in invasive thymoma under retrograde cerebral perfusion. Ann Thorac Surg 1998;66:263-4. [Crossref] [PubMed]
  31. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg 2003;76:878-84. [Crossref] [PubMed]
  32. Momozane T, Inoue M, Shintani Y, et al. Trimodality Therapy for an Advanced Thymic Carcinoma With Both Aorta and Vena Cava Invasion. Ann Thorac Surg 2016;102:e139-41. [Crossref] [PubMed]
  33. Shintani Y, Shimamura K, Funaki S, et al. Combined Aortic Arch Resection for Lung Cancer Using Total Rerouting of Supra-Arch Vessels. Ann Thorac Surg 2019;107:e399-401. [Crossref] [PubMed]
  34. Marulli G, Margaritora S, Lucchi M, et al. Surgical treatment of recurrent thymoma: is it worthwhile? Eur J Cardiothorac Surg 2016;49:327-32. [Crossref] [PubMed]
  35. Hamaji M, Allen MS, Cassivi SD, et al. The role of surgical management in recurrent thymic tumors. Ann Thorac Surg 2012;94:247-54. [Crossref] [PubMed]
  36. Kimura K, Kanzaki R, Kimura T, et al. Long-Term Outcomes After Surgical Resection for Pleural Dissemination of Thymoma. Ann Surg Oncol 2019;26:2073-80. [Crossref] [PubMed]
  37. Lucchi M, Davini F, Ricciardi R, et al. Management of pleural recurrence after curative resection of thymoma. J Thorac Cardiovasc Surg 2009;137:1185-9. [Crossref] [PubMed]
  38. Lucchi M, Mussi A. Surgical treatment of recurrent thymomas. J Thorac Oncol 2010;5:S348-51. [Crossref] [PubMed]
  39. Mizuno T, Okumura M, Asamura H, et al. Japanese Association for Research on Thymus. Surgical management of recurrent thymic epithelial tumors: a retrospective analysis based on the Japanese nationwide database. J Thorac Oncol 2015;10:199-205. [Crossref] [PubMed]
  40. Higashiyama M, Doi O, Kodama K, et al. Intrathoracic chemothermotherapy following panpleuropneumonectomy for pleural dissemination of invasive thymoma. Chest 1994;105:1884-5. [Crossref] [PubMed]
  41. Ishikawa Y, Matsuguma H, Nakahara R, et al. Multimodality therapy for patients with invasive thymoma disseminated into the pleural cavity: the potential role of extrapleural pneumonectomy. Ann Thorac Surg 2009;88:952-7. [Crossref] [PubMed]
  42. Nakamura S, Kawaguchi K, Fukui T, et al. Multimodality therapy for thymoma patients with pleural dissemination. Gen Thorac Cardiovasc Surg 2019;67:524-9. [Crossref] [PubMed]
  43. Shintani Y, Kanzaki R, Kusumoto H, et al. Pleuropneumonectomy for a large thymoma with multiple pleural dissemination using median sternotomy followed by posterolateral thoracotomy. Surg Case Rep 2015;1:75. [Crossref] [PubMed]
  44. Okuda K, Yano M, Yoshino I, et al. Thymoma patients with pleural dissemination: nationwide retrospective study of 136 cases in Japan. Ann Thorac Surg 2014;97:1743-8. [Crossref] [PubMed]
  45. Hamaji M. The role of adjuvant chemotherapy following resection of early stage thymoma. Ann Cardiothorac Surg 2016;5:45-50. [PubMed]
  46. Attaran S, McCormack D, Pilling J, et al. Which stages of thymoma benefit from adjuvant chemotherapy post-thymectomy? Interact Cardiovasc Thorac Surg 2012;15:273-5. [Crossref] [PubMed]
Cite this article as: Funaki S, Shintani Y, Fukui E, Kanzaki R, Kanou T, Ose N, Minami M, Okumura M. Surgical treatment strategies for invasive thymoma. J Thorac Dis 2020;12(12):7619-7625. doi: 10.21037/jtd-19-3045